Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models.
Saved in:
| Title: | Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models. |
|---|---|
| Authors: | Li Y; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Zou Y; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Liang C; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Feng Z; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Lu S; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Wang G; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Meng G; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China. |
| Source: | Frontiers in public health [Front Public Health] 2026 Jun 17; Vol. 14, pp. 1841510. Date of Electronic Publication: 2026 Jun 17 (Print Publication: 2026). |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2296-2565 |
|---|---|
| DOI: | 10.3389/fpubh.2026.1841510 |
